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Abstract
Bone morphogenetic proteins (BMP) are thoughtx to be important in breast cancer promotion and
progression. We evaluated genetic variation in BMP-related genes and breast cancer risk among
Hispanic (2111 cases, 2597 controls) and non-Hispanic white (NHW) (1481 cases, 1586 controls)
women who participated in the 4-Corner’s Breast Cancer Study, the Mexico Breast Cancer Study,
and the San Francisco Bay Area Breast Cancer Study. BMP genes and their receptors evaluated
include ACVR1, AVCR2A, ACVR2B, ACVRL1, BMP1, BMP2, BMP4, BMP6, BMP7,
BMPR1A, BMPR1B, BMPR2, MSTN and GDF10. Additionally, 104 ancestral informative
markers were assessed to discriminate between European and Native American ancestry. The
importance of estrogen on BMP-related associations was suggested through unique associations
by menopausal status and estrogen (ER) and progesterone (PR) receptor status of tumors. After
adjustment for multiple comparisons ACVR1 (8 SNPs) was modestly associated with ER+PR+
tumors [odds ratios (ORs between 1.18 and 1.39 padj< 0.05]. ACVR1 (3 SNPs) and BMP4 (3
SNPs) were associated with ER+PR− tumors (ORs 0.59 to 2.07 padj< 0.05). BMPR2 was
associated with ER−PR+ tumors (OR 4.20, 95% CI 1.62, 10.91 padj< 0.05) as was GDF10 (2
SNPs ORs 3.62 and 3.85 padj< 0.05). After adjustment for multiple comparisons several SNPs
remained associated with ER−PR− tumors (padj< 0.05) including ACVR1 BMP4, and GDF10
(ORs between 0.53 and 2.12). Differences in association also were observed by percentage of
Native ancestry and menopausal status. Results support the hypothesis that genetic variation in
BMPs is associated with breast cancer in this admixed population.
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Introduction
Bone morphogenetic proteins (BMP) are thought to be involved in the initiation and
progression of cancer 1, 2. As members of the TGFβ-signaling pathway they play a critical
role in carcinogenesis through regulation of cell growth, differentiation, proliferation, and
apoptosis 3. Members of the human BMP family include BMP1-7, growth differentiation
factors (GDF) including GDF10 and GDF8 (also known as myostatin) 4 and their receptors.
BMP ligands bind to type 1 and type 2 receptors. Type 1 receptors include BMPR1A,
BMPR1B, activin A receptor type 1 (ACVR1), and activin receptor-like kinase 1
(ACVRL1) ; type II receptors include BMPR2, activin A receptor type IIA (ACVR2A) and
type IIB (ACVR2B) 4. Both types of receptors are needed for BMP signaling, although type
I receptors bind with a higher affinity than the type II receptors. BMPs have been shown to
trigger a SMAD-signaling cascade that is linked to reduced cell proliferation and cellular
growth kinetics of glioblastomas 5, 6 and may play a key role in regulating tumor initiation.
Little is known about the genetic variation in BMP genes and their associations with breast
cancer risk, although these genes have been shown to be important in colorectal cancer7.
Some studies suggest a link of BMPs to breast cancer disease progression and metastasis.
Because of BMPs role in bone formation, they have been examined for their involvement in
metastasis to the bone after diagnosis with breast cancer 8. Additionally BMPs have been
associated with estrogen-induced proliferation of breast cancer cells 9. One study has shown
that BMP-SMAD activation is involved in the progression of estrogen receptor positive (ER
+) breast cancers specifically 10.
In this study, we examined genetic variation in BMP1, BMP2, BMP4, BMP6, BMP7,
Growth Differentiation Factor 10 (GDF10) also known as BMP3B, myostatin (MSTN), and
their relevant receptor genes BMPR1A, BMPR1B, BMPR2, and ACVR1, ACVR2A,
ACVR2B, and ACVRL1. We assessed overall associations as well as associations by ER
and progesterone receptor (PR) status of the tumors and by menopausal status. Given our
ethnically diverse population we also evaluated associations by genetic admixture to
determine whether differences in these genes may contribute to observed ethnic differences
in breast cancer incidence rates.
Methods
The Breast Cancer Health Disparities Study includes participants from three population-
based case-control studies, the 4-Corner’s Breast Cancer Study, the Mexico Breast Cancer
Study, and the San Francisco Bay Area Breast Cancer Study11. All participants signed
informed written consent prior to participation and each study was approved by the
Institutional Review Board for Human Subjects at each institution.
Participants from the 4 Corner’s Breast Cancer Study were NHW, Hispanic, or Native
American women living in non-reservation areas in the states of Arizona, Colorado, New
Mexico, or Utah at the time of diagnosis or selection 12 and included female breast cancer
cases between 25 and 79 years of age with a histological confirmed diagnosis of in situ
(n=341) or invasive (n=1492) cancer between October 1999 and May 2004 and who
provided a blood sample and completed the interview. Controls were selected from the
target populations and were frequency matched to cases on ethnicity and 5-year age
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distribution. Of the 852 Hispanic, 22 American Indian, and 1683 NHW cases and 913
Hispanic, 23 American Indian, and 1669 NHW controls who participated in the interview, a
blood sample for DNA extraction was provided for 76% of participants in Arizona, 71% of
participants in Colorado, 75% of participants in New Mexico, and 94% of participants in
Utah.
Participants from the Mexico Breast Cancer Study were between 28 and 74 years of age,
living in one of three states, Monterrey, Veracruz and Mexico City, for the past five years as
previously described13. Eligible cases were women diagnosed with either a new
histologically confirmed in situ or invasive breast cancer between January 2004 and
December 2007 at 12 participating hospitals from three main health care systems in Mexico.
Controls were randomly selected from the catchment area of the 12 participating hospitals
using a probabilistic multi-stage design. A total of 1000 cases and 1074 controls completed
the in-person interview, and blood was collected and DNA extracted for 85% and 96% of
women, respectively.
The San Francisco Bay Area Breast Cancer Study included women aged 35 to 79 years from
the San Francisco Bay Area diagnosed with a first primary histologically confirmed invasive
breast cancer between 1995 and 2002; controls were identified by random-digit dialing
(RDD) and frequency-matched to cases based on the expected race/ethnicity and 5-year age
distribution.14, 15 This analysis included subjects with bio-specimen collection, including
Hispanic cases diagnosed between April 1997 and April 2002 and a 10% random sample of
NHW cases diagnosed between April 1997 and April 1999 and their matched controls. A
total of 1105 cases (793 Hispanic, 312 NHW) and 1318 controls (998 Hispanic, 320 NHW)
completed the in-person interview, and blood or mouthwash samples were collected and
DNA extracted for 93% of cases and 92% of controls.
Data Harmonization
Data were harmonized across all study centers and questionnaires. Variables used in the
analyses included body mass index (BMI) calculated as weight (kg) divided by height
squared [meters squared (m2)], based on measured height (or self-reported height if the
measurement was declined) and self-reported weight during the referent year or more
distantly recalled weight if referent year weight was not available or measured weight if
neither were available. The referent year was defined as the year prior to diagnosis for cases
or selection for controls. Parity was defined as the number of full-term pregnancies, age at
first birth was defined as age at first live birth or still birth, and race/ethnicity in the U.S.
studies was based on self-report (all women in Mexico were classified as Hispanic since
information on race/ethnicity was not collected). Women were classified as either pre -
menopausal or post-menopausal based on responses to questions on menstrual history.
Women who reported still having periods during the referent year were classified as pre-
menopausal. Center-specific definitions were used to define post-menopausal women.
Women were classified as post-menopausal if they reported a natural menopause. If they
reported taking hormone therapy (HT) and were still having periods and were at or above
the 95th percentile of age for race/ethnicity of those who reported having a natural
menopause (i.e., ≥ 12 months since their last period) within their study center they were
classified as post-menopausal. This age was 58 for NHW and 56 for Hispanics from the 4-
Corner’s Breast Cancer Study, 54 for the Mexico Breast Cancer Study, and 55 for NHW and
56 for Hispanics from the San Francisco Bay Area Breast Cancer Study. Mean daily grams
of alcohol intake consumed over the lifetime were available for all but about 600 cases and
controls from California. For those women we used alcohol consumption during the referent
year as an adjustment variable. Physical activity was harmonized as hours of vigorous
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activity performed at leisure and chores during the referent year and analyzed using center-
specific cut-points to accommodate the level of inquiry of each study questionnaire
Genetic Data
DNA was extracted from either whole blood or mouthwash samples; 7287 blood-derived
and 634 mouthwash-derived samples were available. Whole Genome Amplification (WGA)
was applied to the mouthwash-derived DNA samples prior to genotyping. A tagSNP
approach was used to characterize variation across candidate genes. TagSNPs were selected
using the following parameters: linkage disequilibrium (LD) blocks were defined using a
Caucasian LD map and an r2=0.8; minor allele frequency (MAF) >0.1; range= −1500 bps
from the initiation codon to +1500 bps from the termination codon; and 1 SNP/LD bin.
Additionally, 104 Ancestral Informative Markers (AIMs) were used to distinguish European
and Native American ancestry in the study population11. All markers were genotyped using
a multiplexed bead array assay format based on GoldenGate chemistry (Illumina, San
Diego, California). A genotyping call rate of 99.93% was attained (99.65% for WGA
samples). We included 132 blinded internal replicates representing 1.6% of the sample set.
The duplicate concordance rate was 99.996% as determined by 193,297 matching genotypes
among sample pairs.
In the current analysis, we evaluated 138 SNPs in 14 genes: ACVR1 (16 SNPs), AVCR2A
(6 SNPs), ACVR2B (3 SNPs), ACVRL1 (4 SNPs), BMP1 (10 SNPs), BMP2 (6 SNPs),
BMP4 (4 SNPs), BMP6 (23 SNPs), BMP7 (24 SNPs), BMPR1A (9 SNPs), BMPR1B (18
SNPs), BMPR2 (8 SNPs), MSTN (1 SNPs,) and GDF10 (6 SNPs). Online Supplement 1
describes the SNPs in detail, including the minor allele frequency (MAF) and Hardy-
Weinberg equilibrium (HWE) p value.
Tumor Characteristics
Cancer registries in Utah, Colorado, Arizona, New Mexico, and California provided
information on stage at diagnosis and ER and PR status. Information on ER and PR status
was available for 1019 (69%) NHW cases and 977 (75%) Hispanic cases.
Statistical Methods
The program STRUCTURE was used to compute individual ancestry for each study
participant assuming two founding populations16, 17. A three-founding population model
was assessed but did not fit the population structure with the same level of repeatability and
correlation among runs as the two-founding population model. Participants were classified
by level of percent Native American ancestry. Assessment across categories of ancestry was
done using cut-points based on the distribution of genetic ancestry in the control population
with the goal of creating distinct ancestry groups that had sufficient power to assess
associations. Three strata, 0-28%, 29 to 70%, and 71 to 100%, were used to evaluate
associations by level of Native ancestry. Genetic ancestry was used as a continuous variable
when used to adjust for possible confounding. Genes were assessed for their association
with breast cancer risk by strata of genetic ancestry, ER/PR status, and menopausal status.
All statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC).
Logistic regression models were used to estimate the age, genetic ancestry, and study center-
adjusted odds ratios (OR) and 95% confidence intervals (CI) for breast cancer risk
associated with SNPs. Except for the California study, both invasive and in situ cases were
included given associations that the Mexico Study did not distinguish between these
categories. Additionally, we adjusted for potential confounding variables of BMI, parity, age
at first birth, hours per week of vigorous physical activity, alcohol consumption, and genetic
admixture. SNPs were assessed assuming a co-dominant model. Based on the initial
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assessment, SNPs which appeared to have a dominant or recessive mode of inheritance were
evaluated with those inheritance models in subsequent analyses. Interactions between
genetic variants and genetic ancestry and menopausal status were assessed using p values
from a Wald chi-square test.
Haplotypes were developed to help define risk associated with genes. SNPs were selected
based on their individual significance overall or within a genetic admixture group as well as
for those considered in higher linkage disequilibrium (LD) or an R-squared linkage
disequilibrium measure greater than or equal to 0.5. Haplotypes were estimated using the
EM algorithm. Per-copy haplotype risk estimates were obtained using logistic regression
and adjusted for age, study, genetic admixture, BMI in referent year, age at first birth, parity,
alcohol consumption and vigorous physical activity.
The p values were based on one degree of freedom (1-df) Wald test statistics and were
adjusted for multiple comparisons taking into account tagSNPs within the gene using the
step-down Bonferroni correction (i.e., Holm method). This method isbased on the effective
number of independent SNPs as determined using the SNP spectral decomposition method
proposed by Nyholt 18 and modified by Li and Ji 19. We provide an online Supplement 2
that shows the number of SNPs analyzed and the number of SNPs considered for adjustment
based on correlation between SNPs within a gene. The interaction p values, based on 1-df
Wald chi-square tests, were adjusted using the step-down Bonferroni correction or the
Holm’s test 20. This method of correction for multiple comparisons is very conservative,
especially for correlated variables such as SNPs within a gene. Given that we are assessing
hypothesized associations within a candidate pathway and candidate genes, we considered
an adjusted p value of 0.15 or less as potentially important. However, we include in the text
only those SNPs with adjusted p values of <0.05 and highlight those associations using bold
font in the tables.
Results
The majority of participants were Hispanic (59% of cases and 62% of controls) (Table 1).
More Hispanic women than NHW were diagnosed prior to 40 years of age (9% vs. 6%).
Hispanic cases were more likely to be pre-menopausal at diagnosis than NHW cases (41%
vs. 34%). Hispanic cases were more likely to have ER−PR− tumors than NHW women
(23% vs. 18%).
There were few associations with breast cancer risk overall. However, when we examined
cases defined by ER/PR status, several genes appeared to be associated with specific breast
cancer subtypes (Table 2 shows those that remained significant at the 0.05 level after
multiple comparison adjustment, whereas Supplement 3 shows those that were initially
significant at the 0.05 level but after multiple adjustment testing had adjusted p values of
>0.05). Variants in ACVR1 (8 SNPs) and BMP4 (1 SNP) were associated with ER+PR+
tumors, although the level of association was modest with ORs between 1.19 and 1.33.
ACVR1 (4 SNPs), BMP4 (3 SNPs), and GDF10 (1 SNP) were associated with ER+PR−
tumors, with OR estimates ranging from 0.59 to 2.07. BMPR2 (1 SNP) and GDF10 (2
SNPs) were associated with ER−PR+ tumors (ORs between 3.62 and 4.20). ACVR1 (1
SNP), ACVRL1 (1 SNP), BMP4 (1 SNP), and GDF10 (1 SNP) were associated with ER
−PR− tumors.
Several genes were associated with breast cancer risk within genetic admixture groups
(Table 3). BMP4 rs17563 was associated with breast cancer among women with greater
European ancestry at the 0.05 level or less after adjustment for multiple comparisons.
However, among Hispanic women with low Native American ancestry (0-28%) BMP4
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rs17563 was associated with increased risk (OR 2.42 95% CI 1.40,4.16 for CC vs. TT
genotypes) and BMP6 rs270417 was associated with reduced risk (OR 0.55 95% CI
0.38,0.79 dominant model) (data in Supplement 4 that shows associations for NHW women
and for Hispanic women by admixture category).
ACVR2A rs1014064, rs2161983, rs10497025, and rs3768687, and ACVR2B rs928813 and
rs2276541 were associated with breast cancer among those with the greatest Native
American ancestry; the ACVR2B associations were statistically different from those
observed for women with more European ancestry. ACVR2A rs10497025, BMP4 rs762642,
and rs2761887, BMP7 rs7273197, and BMPR2 rs17199235 were associated with breast
cancer in the intermediate ancestry group.
Haplotype analysis showed rare haplotypes to carry some risk beyond SNPs themselves
(Table 4). For the ACVR1 the rare A-T haplotype of rs4380178 and rs17182166 (0.028% of
the population) was associated with an OR of 1.51 (95% CI 1.14,2.00). The rare C-T-A-G
haplotype of BMP6 rs10498671, rs1225929, rs1107495, and rs911749 which occurred in
0.012% of the population was associated with reduced breast cancer risk (OR 0.34, 95% CI
0.19,0.62). Among the highest Native ancestry group, two haplotypes of BMP7 were
associated with increased breast cancer risk: BMP7 rs174080735, rs6025446, and rs6025468
A- A-A (0.014% of the population) OR 2.25 (95% CI 1.11,4.58) and BMP7 rs6127983 and
rs6025468 T-G (0.008% of the population) (OR 4.55 95% CI 1.09,19.00). Additional
haplotypes based on SNPs in higher LD also were identified as being statistically
significant. These haplotypes were observed in less than 5% of the population and were
primarily in BMP6 and BMP7.
We observed differences in association by menopausal status for several genes; Figure 1
shows those associations that remained significant at the 0.05 level after adjustment for
multiple comparisons. Supplement 5 shows all associations that were significant prior to
adjustment along with the associated unadjusted and adjusted p values. For women with low
Native American ancestry, ACVR1 rs1220134 and ACVR2A rs10497025 were associated
with reduced breast cancer risk and BMRP1B rs1863652 was associated with increased risk
among pre-menopausal women, whereas BMP4 rs17563 was associated with increased
breast cancer risk among post-menopausal women. Breast cancer risk was different for pre-
menopausal and post-menopausal women for several genes among women with the highest
level of Native American ancestry. Among pre-menopausal women, ACVR2B rs2276541
was associated with reduced risk whereas rs928813 was associated with increased risk.
Among post-menopausal women ACVR2B rs503327 and GDF10 rs1902725 were
associated with increased risk. ACVR2A rs1097025, BMP4 rs762642 and rs2761887,
BMP7 rs7273197, and BMPR2 rs17199235 showed differences in risk by menopausal status
among women in the intermediate ancestry category.
Discussion
BMPs are extracellular signaling molecules and are the largest group of the TGFβ
superfamily. Because of their role in cell regulation, proliferation, apoptosis, and migration,
they have been implicated as potentially important in cancer etiology. Our data suggest that
genetic variation in BMPs and their receptors are involved in breast cancer etiology and
prognosis. Few SNPs were associated overall with breast cancer risk after adjustment for
multiple comparisons and associations were very modest. However, several BMPs and their
receptors were associated with specific ER and PR tumor phenotype and the associations
were generally stronger for specific subtypes than for breast cancer risk. Additionally we
observed unique associations by genetic ancestry as well as by menopausal status.
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BMPs have been associated with estrogen in several studies, some of which have linked
BMPs to expression of estrogen receptors and estrogen signaling 21. BMP6 and BMP7 have
been shown to inhibit estrogenic enzyme expression 9. Helms and colleagues 10 have
reported that BMPR1B is involved in the progression and differentiation of ER-positive
breast cancer. BMP6 and BMP7 preferentially bind to BMPR1B and ACVR1. Estrogen also
has been shown to reduce expression of BMPR1A, BMPR1B, ACVR2A, and ACVR2B 9.
BMP7 has been shown to be associated with expression of both the estrogen and
progesterone receptor 22. In another study, hypermethylation of BMP6 was observed in all
ER-negative breast cancers, but in only 18% of ER-positive breast cancers, suggesting a
correlation between BMP6 expression and ER status of breast cancers23. BMP6 also has
been shown to inhibit ER –induced mitosis 9; BMP2 has been associated with ER-negative
tumors 24. Our results add to the knowledge about the association between BMPs and their
receptors and risk of breast cancer defined by hormone receptors. Overall we observed few
associations with BMP6 and BMP7 that remained significant after adjustment for multiple
comparisons given the size of the genes and number of SNPs assessed. However, rare
haplotypes of these genes were associated with breast cancer risk, primarily among women
with intermediate and high Native American ancestry. Given associations observed between
menopausal status and ER/PR tumor status, we believe that our data support the findings by
Takahashi and Wang that showed the importance of BMP receptors and estradiol9, 25. Many
of our associations by ER and PR status were observed for type 1 receptors (ACVR1 and
ACVRL1). Most SNPs in these genes appeared to be more strongly associated with ER+
tumors than ER− tumors. However, for some SNPs associations were stronger for ER−
tumors, and for some the associations were similar for ER− PR− tumors (e.g. ACVR1
rs17182166, ACVRL1 rs11169953, BMP4 rs17563, GDF10 rs762454). Several SNPs were
associated with ER− PR+ tumors (BMPR2 rs12621870, and GDF10 rs7093975 and
rs2853838).
In our assessment of genetic associations by menopausal status, we observed differences in
risk by genetic admixture within menopausal groups. While no associations were observed
for BMP7 and ER/PR tumor status, three SNPs were associated with decreased risk of pre-
menopausal breast cancer risk among women in the intermediate admixture group and one
SNP was associated with post-menopausal breast cancer risk among women with more
Native American ancestry. BMP6 rs1225929 was associated with post-menopausal breast
cancer among women in the middle admixture group, and BMP6 rs270417 was associated
with pre-menopausal breast cancer for those with the most Native ancestry. Most
associations found were with type 1 and type 2 BMP receptors, again stressing the
importance of receptors in the estrogen-related associations with BMPs 9.
We and others have previously reported that women with higher Native ancestry were at
reduced risk of breast cancer11, 26-28. Given this difference in risk, it is of interest to
determine whether unique genetic factors are associated differently with breast cancer based
on genetic admixture. For the most part we found that associations with BMP-related genes
did not differ by genetic admixture. Among those that did, we observed generally stronger
risk estimates and more associations with increasing Native American ancestry, with the
exception of BMP4 rs17563 which was associated among women with more European
ancestry. Others have not examined these genes in similar admixed populations.
The study is the largest to date reporting associations with breast cancer in a genetically
admixed population of European and Native American ancestry. We were able to evaluate
associations by genetic admixture as well as by ER/PR status of tumors. However, the study
has some limitations. Data on tumor characteristics were not available for the entire study
population, which restricted our ability to evaluate these characteristics across the same
genetic admixture spectrum as we did for the analysis of SNP and breast cancer risk
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associations. Additionally, we were limited in power to evaluate some tumor phenotypes, for
instance there were only 43 cases of ER−PR+ tumors. We evaluated SNPs in several
candidate genes. While we hypothesized associations with specific genes, we were limited
in our ability to make similar hypotheses regarding specific SNPs. Although we adjusted for
multiple comparisons, it is possible that associations are spurious, and thus replication in
other studies is needed. Additionally, we have limited information on functionality of these
SNPs and our interpretation of findings is greatly guided by the literature on BMPs and their
association with cancer in general.
Our findings support the role of genetic variation in BMPs in the etiology of breast cancer.
Associations of BMP-related SNPs were in some instances influenced by menopausal status
and resulted in associations that were specific to ER and PR status of tumors. Overall, BMP
genes were more commonly associated with breast cancer in women with more Native
American ancestry, suggesting the importance of genetic ancestry to understanding risk
associated with breast cancer. Studies to confirm these findings are needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Description of Study Population by Self-reported Race/Ethnicity
NHW Hispanic
Controls Cases Controls Cases
N % N % N % N %
Total 1586 37.9 1481 41.2 2597 62.1 2111 58.8
Study Site
 4 Corner’s States 1322 83.4 1227 82.8 723 27.8 597 28.3
 Mexico 0 0.0 0 0.0 994 38.3 816 38.7
 California 264 16.6 254 17.2 880 33.9 698 33.1
Age (years)
 <40 116 7.3 89 6.0 311 12.0 200 9.5
 40-49 408 25.7 409 27.6 831 32.0 713 33.8
 50-59 409 25.8 413 27.9 756 29.1 617 29.2
 60-69 350 22.1 361 24.4 526 20.3 430 20.4
 70+ 303 19.1 209 14.1 173 6.7 151 7.2
 Mean 56.6 56.0 52.3 52.7
Menopausal Status
 Pre-menopausal 494 31.5 489 33.5 1027 40.7 836 40.9
 Post-menopausal 1076 68.5 970 66.5 1499 59.3 1210 59.1
Estimated Native American Ancestry
 Low (0 - 28%) 1578 99.5 1472 99.4 278 10.7 275 13.0
Intermediate (29 - 70%) 7 0.4 7 0.5 1686 64.9 1393 66.0
High (71 - 100%) 1 0.1 2 0.1 633 24.4 443 21.0
ER/PR Status*
 ER+PR+ NA 695 68.2 NA 605 61.9
 ER+PR− NA 121 11.9 NA 115 11.8
 ER−PR+ NA 15 1.5 NA 28 2.9
 ER−PR− NA 188 18.4 NA 229 23.4
*
Tumor information was unavailable for the Mexico study sites.
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